title: Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
abstract: The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. The short- and long-term metabolic safety of sertindole was compared to that of risperidone in a subset of patients enrolled in the sertindole cohort prospective (SCoP) study, an open randomized study. In 261 randomized patients, there were moderate increases in mean weight, BMI, and waist circumference during treatment with either sertindole or risperidone; after 12 weeks, the increase in weight was 1.3 and 1.1 kg, respectively, and after 36 weeks, it was 2.2 and 2.0 kg, respectively. From baseline to last assessment (up to 60 weeks), weight gains of 1.8 and 1.7 kg for sertindole and risperidone, respectively, were observed. Similar proportions of patients (sertindole: 17% versus risperidone: 16%) had weight increases ≥7% from baseline to last assessment. The mean changes from baseline in triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, plasma glucose and blood pressure were small and not clinically relevant in both treatment groups. No patient in either of the groups developed type 2 diabetes during the study. At last assessment, the prevalence of metabolic syndrome (International Diabetes Federation) was 17% in the sertindole group and 26% in the risperidone group and the incidence of metabolic syndrome was 7% in the sertindole group and 10% in the risperidone group. Treatment with either sertindole or risperidone did not appear to be associated with an increased comparative risk of developing metabolic syndrome. In general, the metabolic effects of sertindole and risperidone were similar.
authors.affiliation: University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, Kortenberg, Belgium. marc.de.hert@uc-kortenberg.be
authors.forename: Marc
authors.initials: M
authors.lastname: De Hert
authors.forename: Aurélia
authors.initials: A
authors.lastname: Mittoux
authors.forename: Yuan
authors.initials: Y
authors.lastname: He
authors.forename: Joseph
authors.initials: J
authors.lastname: Peuskens
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D016009:Chi-Square Distribution; D005215:Fasting / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D012737:Sex Factors; D013997:Time Factors; D055105:Waist Circumference / Q000187:drug effects; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007093:Imidazoles; D007211:Indoles; D008055:Lipids; C066304:sertindole; D018967:Risperidone
references.citation: Int J Clin Pract. 2007 Aug;61(8):1356-70
references.pmid: 17627711
references.citation: Schizophr Res. 2008 Oct;105(1-3):175-87
references.pmid: 18775645
references.citation: Am Heart J. 2005 Dec;150(6):1115-21
references.pmid: 16338246
references.citation: Diabetes Care. 2001 Apr;24(4):683-9
references.pmid: 11315831
references.citation: Schizophr Res. 2005 Dec 1;80(1):45-53
references.pmid: 16198088
references.citation: CNS Drugs. 2005;19 Suppl 1:1-93
references.pmid: 15998156
references.citation: Schizophr Res. 2005 Nov 15;79(2-3):281-8
references.pmid: 15964743
references.citation: J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20
references.pmid: 15151456
references.citation: J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S1-6
references.pmid: 15356414
references.citation: Schizophr Res. 2010 Mar;117(1):68-74
references.pmid: 20060684
references.citation: Diabetes Metab. 2007 Jun;33(3):169-75
references.pmid: 17412628
references.citation: Schizophr Res. 2000 Sep 29;45(1-2):21-8
references.pmid: 10978869
references.citation: Lancet. 2009 Aug 22;374(9690):620-7
references.pmid: 19595447
references.citation: Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
references.pmid: 17909124
references.citation: Schizophr Res. 2006 Sep;86(1-3):15-22
references.pmid: 16884895
references.citation: Acta Psychiatr Scand. 2010 Nov;122(5):345-55
references.pmid: 20384598
references.citation: Int J Psychiatry Clin Pract. 2002;6(1):27-32
references.pmid: 24931887
references.citation: J Psychopharmacol. 2007 Jun;21(4):357-73
references.pmid: 17656425
references.citation: J Am Coll Cardiol. 2005 Jul 5;46(1):173-5
references.pmid: 15992653
references.citation: Eur Arch Psychiatry Clin Neurosci. 2010 Feb;260(1):59-68
references.pmid: 19455275
references.citation: Eur Psychiatry. 2009 Sep;24(6):412-24
references.pmid: 19682863
references.citation: Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):804-11
references.pmid: 17551996
references.citation: Clin Pract Epidemiol Ment Health. 2006 Jun 27;2:14
references.pmid: 16803620
references.citation: Acta Psychiatr Scand. 2009 Jan;119(1):4-14
references.pmid: 19133915
references.citation: J Psychiatr Res. 2009 Sep;43(13):1106-11
references.pmid: 19398113
references.citation: Schizophr Res. 2008 Apr;101(1-3):273-86
references.pmid: 18258416
references.citation: Lancet. 2009 Jan 3;373(9657):31-41
references.pmid: 19058842
references.citation: Am J Psychiatry. 2009 Feb;166(2):152-63
references.pmid: 19015230
references.citation: Acta Psychiatr Scand. 2007 Nov;116(5):317-33
references.pmid: 17919153
references.citation: Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7
references.pmid: 18041878
references.citation: Am J Psychiatry. 2004 Aug;161(8):1334-49
references.pmid: 15285957
references.citation: Pharmacoepidemiol Drug Saf. 2008 May;17(5):425-33
references.pmid: 18384186
references.citation: Diabetes Care. 2004 Feb;27(2):596-601
references.pmid: 14747245
references.citation: Schizophr Res. 2009 Aug;113(1):1-11
references.pmid: 19524406
references.citation: J Clin Psychiatry. 2008 Apr;69(4):514-9
references.pmid: 18370570
references.citation: Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5
references.pmid: 16601508
references.citation: BMJ. 2000 Aug 19-26;321(7259):483-4
references.pmid: 10948028
references.citation: Int J Psychiatry Clin Pract. 2000;4(1):47-54
references.pmid: 24927312
references.citation: Expert Opin Pharmacother. 2006 Sep;7(13):1825-34
references.pmid: 16925508
references.citation: Am J Psychiatry. 1997 Jun;154(6):782-91
references.pmid: 9167505
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: J Clin Psychiatry. 2009 Jul;70(7):1041-50
references.pmid: 19653979
references.citation: J Clin Psychiatry. 2006 Oct;67(10):1493-500
references.pmid: 17107239
references.citation: Arch Gen Psychiatry. 2009 Jul;66(7):713-20
references.pmid: 19581562
references.citation: Diabet Med. 2006 May;23(5):469-80
references.pmid: 16681555
references.citation: Schizophr Res. 2008 Apr;101(1-3):295-303
references.pmid: 18299188
references.citation: Circulation. 2005 Oct 25;112(17):2735-52
references.pmid: 16157765
references.citation: Lancet. 2004 Sep 11-17;364(9438):937-52
references.pmid: 15364185
references.citation: World Psychiatry. 2009 Feb;8(1):15-22
references.pmid: 19293950
references.citation: Am J Psychiatry. 2009 Mar;166(3):345-53
references.pmid: 19147694
references.citation: Br J Psychiatry. 2008 Jun;192(6):406-11
references.pmid: 18515889